Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) is expected to release its Q2 2025 earnings data after the market closes on Wednesday, August 6th. Analysts expect Neumora Therapeutics to post earnings of ($0.38) per share for the quarter.
Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.02). On average, analysts expect Neumora Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Neumora Therapeutics Price Performance
Shares of NMRA traded down $0.11 during mid-day trading on Wednesday, hitting $2.08. 1,006,753 shares of the company's stock were exchanged, compared to its average volume of 2,181,286. The company has a market cap of $336.44 million, a PE ratio of -1.29 and a beta of 2.75. Neumora Therapeutics has a 52 week low of $0.61 and a 52 week high of $17.19. The company has a 50-day simple moving average of $1.08 and a 200 day simple moving average of $1.21.
Analyst Ratings Changes
NMRA has been the subject of several analyst reports. Needham & Company LLC reissued a "buy" rating and issued a $5.00 target price on shares of Neumora Therapeutics in a research note on Tuesday, May 13th. Bank of America reaffirmed an "underperform" rating and set a $1.00 price target (down previously from $7.00) on shares of Neumora Therapeutics in a report on Wednesday, April 2nd. Finally, Mizuho raised their price target on Neumora Therapeutics from $4.00 to $5.00 and gave the company an "outperform" rating in a report on Wednesday, July 16th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $7.14.
Get Our Latest Research Report on Neumora Therapeutics
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Neumora Therapeutics stock. Invesco Ltd. lifted its position in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 151.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 123,655 shares of the company's stock after purchasing an additional 74,406 shares during the period. Invesco Ltd. owned about 0.08% of Neumora Therapeutics worth $124,000 as of its most recent filing with the Securities and Exchange Commission. 47.65% of the stock is owned by hedge funds and other institutional investors.
About Neumora Therapeutics
(
Get Free Report)
Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Further Reading
Before you consider Neumora Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neumora Therapeutics wasn't on the list.
While Neumora Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
